Clinical trials continue to be a cornerstone to the effort to advance care and improve outcomes for cancer patients. ECOG and ACRIN collectively have over 65 years of experience conducting high impact clinical trials that have helped shaped clinical practice. In response to the National Clinical Trials Network (NCTN) initiative, ECOG and ACRIN have merged their complementary scientific programs to form the ECOG-ACRIN Cancer Research Group (E-A). We propose a program focused on the efficient development and implementation of practice-changing science along the cancer care continuum from early detection through treatment of advanced disease. We take advantage of combined expertise in imaging, cancer biology and therapy within our scientific organization, working closely with the biostatistics and data management center at the Dana Farber Cancer Institute and Brown University, to propose a portfolio of treatment and advance imaging trials that recognize the importance of biomarkers to identify appropriate patient subgroups for precisely targeted intervention. The E-A biorepositories, image database and associated translational science centers will leverage the data collected in the context of trials to perform correlative science studies that advance our understanding of cancer biology and treatment effect. We continue to seamlessly integrate with Cancer Center and SPORE research programs to create an interface for translating NCI-supported science into clinical trials and to attract junior investigators intothe NCTN. We propose to continue collaborating across the NCTN, contributing high quality trials, leadership in advance imaging, joint trial development and important NCTN operational infrastructure. E-A will leverage unique clinical informatics expertise to contribute a data warehouse of annotated images and specimens, laboratory analytics and clinical data to foster scientific discovery. E-A will contribute an accrual network of 37 main member institutions, 200 affiliates, 36 CCOPs and minority-based CCOPs that have accrued 33750 patients to clinical trials over the last 6 years. E-A is positioned to make unique contributions to the NCTN, working to translate NCI-supported science into improved outcomes for cancer patients.

Public Health Relevance

The primary goal of ECOG-ACRIN is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180820-04
Application #
9243123
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-29
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ecog-Acrin Medical Research Foundation
Department
Type
DUNS #
078579855
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Ratai, Eva-Maria; Zhang, Zheng; Fink, James et al. (2018) ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy. PLoS One 13:e0198548
Morgans, Alicia K; Chen, Yu-Hui; Sweeney, Christopher J et al. (2018) Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. J Clin Oncol 36:1088-1095
King, Rebecca L; Nowakowski, Grzegorz S; Witzig, Thomas E et al. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J 8:27
Sparano, Joseph A (2018) Prognostic gene expression assays in breast cancer: are two better than one? NPJ Breast Cancer 4:11
Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2018) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol 41:588-594
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Marcelletti, John F; Sikic, Branimir I; Cripe, Larry D et al. (2018) Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia. Cytometry B Clin Cytom :
Meropol, Neal J; Feng, Yang; Grem, Jean L et al. (2018) Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). Cancer 124:688-697
Miller, Kathy D; O'Neill, Anne; Gradishar, William et al. (2018) Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol 36:2621-2629

Showing the most recent 10 out of 260 publications